Mammalian cell line development is essential to biologics manufacturing, ensuring stable, high-yield expression of therapeutic proteins. With expanding biologics pipelines, the industry is continuously innovating to improve productivity, speed to patient, and scalability. Among the most widely used cell lines for biologics production are Chinese Hamster Ovary (CHO) cells, which have become the gold standard for monoclonal antibody and recombinant protein production. Their adaptability, scalability, and ability to achieve high titers make them essential for developing monoclonal antibodies and other complex biologics.

Cell Line Development Steps for Monoclonal Antibody Production Developing a stable, high-yield cell line requires multiple steps, including the genetic modification of mammalian cells to integrate the gene encoding the protein of interest into the host genome. This is followed by rigorous screening, characterisation, and banking to ensure high productivity and product stability.